Welcome to our dedicated page for Privia Health Group news (Ticker: PRVA), a resource for investors and traders seeking the latest updates and insights on Privia Health Group stock.
Privia Health Group, Inc. (PRVA) delivers technology-enabled physician partnership solutions transforming healthcare delivery. This news hub provides investors and industry observers with essential updates on the company's operational developments and strategic direction.
Access timely PRVA press releases covering earnings announcements, value-based care initiatives, and technology partnerships. Our curated collection helps stakeholders track:
• Financial Updates: Quarterly results and SEC filings
• Operational Milestones: Practice network expansions and platform enhancements
• Strategic Collaborations: Health system partnerships and technology integrations
• Industry Recognition: Awards and quality care achievements
Bookmark this page for objective reporting on PRVA's physician enablement strategies and cloud-based healthcare solutions. Verify compliance updates and leadership changes through our maintained news archive.
Privia Health Group, Inc. (Nasdaq: PRVA) will release its financial results for Q1 2022 on May 12, 2022, before market opening. The press release will be available at 7:00 am ET on their Investor Relations website. Management will host a conference call at 8:30 am ET to discuss the results and future outlook, accessible via webcast or by dialing 855-940-5315. An archive of the webcast will be available shortly after the call concludes. Privia Health focuses on optimizing physician practices and improving patient experiences through technology-driven solutions.
Privia Health Group, Inc. (Nasdaq: PRVA) announced the appointment of Nancy Cocozza to its Board of Directors, expanding the board to ten members. Cocozza, a former Medicare business leader at Aetna, will also join the Audit Committee. CEO Shawn Morris highlighted her extensive healthcare industry expertise as a key asset for the company's growth in value-based care. Cocozza expressed enthusiasm for contributing to the company’s success. With over 30 years of experience, she brings valuable insights to tackle healthcare challenges.
Privia Health Group, Inc. (Nasdaq: PRVA) reported strong financial results for FY 2021, exceeding guidance with total revenue of $966.2 million, a 18.3% increase year-over-year. The fourth quarter revenue rose 28.8% to $275.3 million. Despite an operating loss of $217.4 million for FY 2021, non-GAAP adjusted net income was $41.6 million. The company anticipates continued growth with FY 2022 guidance projecting practice collections to reach between $2.05B and $2.2B, reflecting a 26.1%-35.3% increase. Additionally, new market entries and ACO expansions are expected to enhance profitability.
Amalgam Rx and Privia Health have announced a collaboration to enhance provider workflows through EHR-integrated services. This partnership aims to simplify value-based care, clinical trial recruitment, and medication safety. Notable offerings from Amalgam include Payer Configured Value-Based Care Rules, Clinical Trial Recruitment tools, and Medication Safety algorithms. This collaboration aligns with Privia's strategy to reduce costs and improve patient outcomes as it moves towards value-based care.
ARLINGTON, Va., Feb. 15, 2022 — Privia Health Group (Nasdaq: PRVA) will participate in a virtual fireside chat during the SVB Leerink 11th Annual Global Healthcare Conference on February 16, 2022, at 4:20 pm ET. The event will be accessible through a webcast along with a replay and accompanying slide presentation available on their website.
Privia Health is a technology-driven company focused on enhancing physician practices, patient experiences, and healthcare outcomes.
On February 14, 2022, Javara announced a clinical trial for an investigational vaccine, mRNA-1345, aimed at preventing respiratory syncytial virus (RSV) in adults aged 60 and older. This trial, conducted in partnership with Privia Health and Moderna (Nasdaq: MRNA), will enroll approximately 34,000 participants across Fayetteville, Annapolis, and Fort Worth. RSV causes significant health issues, with over 177,000 hospitalizations yearly among older adults in the U.S. The trial aims to evaluate the vaccine's safety and efficacy, addressing the urgent need for preventive measures against RSV.
Privia Health Group, Inc. (Nasdaq: PRVA) and Surgery Partners, Inc. (Nasdaq: SGRY) announced a strategic partnership to enhance healthcare delivery in Montana. This agreement grants Privia access to the Great Falls Clinic, a multi-specialty practice with 65 providers, serving as a base for building a statewide network.
Privia Health will also manage the newly established Privia Management Company of Montana, focusing on clinical operations and performance services. The partnership aims to improve patient care while expanding both companies' operational capacities in Montana.
ARLINGTON, Va., Jan. 31, 2022 - Privia Health Group, Inc. (Nasdaq: PRVA) will release its fourth quarter and full year financial results for 2021 on March 25, 2022, before the market opens. The press release will be available at ir.priviahealth.com by 7:00 AM ET. Following this, the management will hold a conference call at 8:00 AM ET to discuss the results and future outlook. Interested parties can access the call via a webcast or by phone. The recording will be available for replay shortly after the call.
Privia Health Group, Inc. (Nasdaq: PRVA) has launched three new Accountable Care Organizations (ACOs) in Maryland, Florida, and Tennessee, bringing the total to seven ACOs in its portfolio. Effective January 1, 2022, the Privia Quality Network now includes over 1,900 independent providers serving 168,000+ Medicare beneficiaries. Four ACOs have transitioned to the MSSP Enhanced Track, which entails significant financial risks. In 2020, Privia achieved $86.5 million in shared savings through MSSP, with total savings exceeding $576 million since 2014.
Privia Health Group, Inc. (Nasdaq: PRVA) has appointed Jeffrey S. Sherman as Executive Vice President and Chief Financial Officer, effective immediately. Sherman, who brings significant financial and healthcare experience from previous roles, will oversee finance and accounting activities. Privia Health CEO Shawn Morris emphasized that Sherman’s background will support the company’s growth and long-term value creation. Sherman succeeds David Mountcastle, who is leaving the company after a successful tenure. Privia Health focuses on optimizing physician practices and enhancing patient experiences.